New Approaches in the Treatment and
Management of Idiopathic Pulmonary Fibrosis
A continuing medical education
activity provided by NAMCP and AAMCN
This activity is an archive from the live session from the 2020
Spring Managed Care Forum. If you participated in the live session,
you are not eligible for continuing education credits from this
This activity is valid from August 1, 2020 to August 1, 2021
Instructions for CME/NCPD: Complete the pre-test, listen to the
audio and view the slides, complete the post test, complete the
evaluation form and hit submit. You will be asked to enter your name
and email address on the pre-test, evaluation and post-test. If you
close your internet browser without completing the post test, you
will have ONE more opportunity to complete. A score of 70% must be
achieved on the post test to receive continuing education credits.
If you do not pass the post test after two attempts, you will not be
eligible to try again. Once you complete the evaluation form and
score 70% or higher on your post test, you will automatically be
given your certificate.
To print or save your certificate, you will need to click on the
“download” button and either print or save.
This activity is intended for healthcare professionals practicing in
managed care environments.
This activity is supported by
an educational grant from
Idiopathic pulmonary fibrosis (IPF) is a chronic, progressive
fibrosing interstitial lung disease (ILD) of unknown origin
characterized by progressive lung scarring. It is the most common of
the idiopathic interstitial pneumonias, and is a devastating disease
associated with irreversible destruction of the lung. The scarring
in the lungs gets progressively worse and it makes it difficult for
patients to breathe as well as keep adequate levels of oxygen in the
bloodstream. The condition affects approximately 3 million people
worldwide and has a substantial burden to patients, their families,
and the overall healthcare system. Patients with IPF can progress
slowly with the right treatment, while others experience rapid lung
decline, which presents several diagnostic and management-related
challenges. IPF typically has a poor prognosis and the median
survival rate is less than four years or fewer from diagnosis. Most
patients with idiopathic pulmonary fibrosis present with a gradual
onset, which makes it difficult to diagnosis early.
The diagnosis of IPF in most cases involves an in-depth review of
both medication and environmental exposure histories followed by a
high-resolution computed tomography scan (HRCT). Depending on the
results of the HRCT, an analysis of the bronchoalveolar lavage fluid
or surgical lung biopsy may be performed, and with a proper
evaluation of the HRCT results combined with a histopathology
pattern, confirms a diagnosis of IPF. Once the diagnosis is
confirmed, the goals of IPF management are to ameliorate symptoms,
improve health status, preserve lung function, maintain adequate
oxygenation with supplemental oxygen, minimize adverse events of
therapy, reduce the frequency of acute exacerbations and, ideally,
improve overall patient care and outcomes. Treatment strategies for
IPF aim at managing the symptoms and slowing disease progression to
best maintain a patient’s quality of life. There continue to be
advancements in the current treatment regimens. More recently,
therapeutic options for IPF have evolved to include targeted agents
that have the ability to individualize treatment for patients.
Upon completion of this
activity, participants will be able to:
Evaluate the current guideline
recommendations for managing patients with idiopathic pulmonary
Assess multidisciplinary tactics for
the most accurate screening and diagnostic evaluation of
patients of IPF
Analyze the evidence on the
efficacy, safety, and utility of antifibrotic therapies for IPF
to guide personalized treatment decisions
Describe the clinical impact of
emerging therapies for patients with IPF
Explore the limitations of current
management approaches for IPF and identify effective strategies
to achieve optimal outcomes
||Steven Nathan, MD
Advanced Lung Disease and Transplant Program
Inova Fairfax Hospital
Professor of Medicine
Virginia Commonwealth University
serves on an advisory board for Boehringer Ingelheim and
Genentech. He serves as a consultant for Boehringer
Ingelheim, Bellerophon, Galapagos, Genentech, and United
Therapeutics. His presentation has been peer reviewed
for any bias.
MD has no real or perceived financial relationships to
Jeremy Williams has no real or perceived financial
relationships to disclose.
Jacqueline Cole, RN, MS, CMCN has no real or perceived
financial relationships to disclose.
NAMCP and/or the presenter
has copyright or has received permissions for use of
materials provided in this activity.
Accreditation & Designation
This activity has been planned and implemented in accordance with
the accreditation requirements and policies of the Accreditation
Council for Continuing Medical Education (ACCME) through the joint
providership of the National Association of Managed Care Physicians
(NAMCP) and American Association of Managed Care Nurses (AAMCN). The
National Association of Managed Care Physicians is accredited by the
ACCME to provide continuing medical education for physicians.
NAMCP designates this enduring material for a maximum of 1 AMA
PRA Category 1 credit(s)TM. Each
physician should claim credit commensurate with the extent of their
participation in the activity.
The American Association of Managed Care Nurses is accredited as a
provider of nursing continuing professional development by the
American Nurses Credentialing Center's Commission on Accreditation.
Nurses who complete this activity and achieve a passing score will
receive 1 hour in nursing continuing professional development.
This activity has been approved by the American Board of Managed
Care Nursing for 1.0 contact hours toward CMCN recertification
This activity is supported by
an educational grant from
NAMCP and/or this website does not
provide medical advice, diagnosis or treatment. NAMCP does not
endorse or imply endorsement of the content on any linked website.
This website is to be used as an informational resource. With any
health related concern, consult with your physician or healthcare
Click Here To Continue